Development associated factors with polyneuropathy, myopathy and polyneuromyopathy in critically ill adult patients
DOI:
https://doi.org/10.28957/rcmfr.396Keywords:
Polyneuropathies, diseases of the peripheral nervous system, muscle weakness, muscle atrophyAbstract
Introduction. Polyneuropathy, myopathy, and polyneuromyopathy are debilitating conditions that affect critically ill patients. However, little is known about the factors related to these outcomes in patients hospitalized in intensive care units (ICUs) and with prolonged hospitalization in the Colombian clinical context.
Objective. To assess the factors associated with the development of polyneuropathy, myopathy and polyneuromyopathy in critically ill patients with prolonged hospitalization.
Methods. Analytical, observational, matched case-control study conducted in 192 patients (64 cases and 128 controls) treated at a tertiary care clinic in Cali, Colombia. Different risk factors such as multi-organ failure, sepsis, malnutrition, parenteral nutrition, use of corticosteroids, use of muscle relaxants, among others, were analyzed. We assessed whether the length of stay in the ICU is a modifier of the effect of the relationship between these factors and the outcomes.
Results. It was found that multiorgan failure (OR: 6.32, 95%CI: 2.15-18.58), malnutrition (OR: 2.25, 95%CI: 1.01-5.0) and the use of muscle relaxants (OR: 2.68, 95%CI: 1.04-6.87) were associated with the development of polyneuropathy and myopathy. Likewise, it was observed that the association between multi-organ failure and these conditions was affected by the length of stay in the ICU (p<0.05). In patients without multi-organ failure, the risk increased minimally with each additional day of stay in the ICU (OR: 1.004, 95%CI: 0.97-1.04); however, in patients with multi-organ failure, the risk increased by 5% for each additional day of stay in the ICU.
Conclusions. The results of the present study highlight the importance of factors such as multi-organ failure, malnutrition and the use of muscle relaxants in the development of polyneuropathy, myopathy and polyneuromyopathy in critically ill patients with prolonged hospitalization.
References
Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care. 2008;12(6):238. Disponible en: https://doi.org/10.1186/cc7100.
Apostolakis E, Papakonstantinou NA, Baikoussis NG, Papadopoulos G. Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients. J Anesth. 2015;29(1):112-21. Disponible en: https://doi.org/10.1007/s00540-014-1875-x.
Zhou C, Wu L, Ni F, Ji W, Wu J, Zhang H. Critical illness polyneuropathy and myopathy: a systematic review. Neural Regen Res. 2014;9(1):101-10. Disponible en: https://doi.org/10.4103/1673-5374.125337.
García-de Lorenzo AG De, Vilas E, Rodríguez-Montes JA. Fisiopatología de las alteraciones neuromusculares en el paciente crítico. Nutr Hosp. 2006;21(Suppl 3):96-103.
Mehrholz J, Pohl M, Kugler J, Burridge J, Mückel S. Physical rehabilitation for critical illness myopathy and neuropathy. Cochrane Database Syst Rev. 2014;2014(1):CD10942. Disponible en: https://doi.org/10.1002/14651858.CD010942.
de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med. 2001;29(12):2281-6. Disponible en: https://doi.org/10.1097/00003246-200112000-00008.
Tennilä A, Salmi T, Pettilä V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med. 2000;26(9):1360-3. Disponible en: https://doi.org/10.1007s001340000586.
Piva S, Fagoni N, Latronico N. Intensive care unit-acquired weakness: unanswered questions and targets for future research. F1000Res. 2019;8. Disponible en: https://doi.org/10.12688/f1000research.17376.1.
Enciso C, Ojeda E, Castro F. Polineuropatía y miopatía en el paciente crítico: Revisión de literatura. Repert. Med. Cir. 2013;22(3):158-67. Disponible en: https://doi.org/10.31260/RepertMedCir.v22.n3.2013.762.
Medical Research Council. Aids to the examination of the peripheral nervous system. London: Medical Research Council; 1976.
MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet. 1977;2(8038):615. Disponible en: https://doi.org/10.1016/s0140-6736(77)91471-4.
Burnham EL, Moss M, Ziegler TR. Myopathies in critical illness: Characterization and nutritional aspects. J Nutr. 2005;135(7):1818S-23S. Disponible en: https://doi.org/10.1093/jn/135.7.1818S.
Shepherd S, Batra A, Lerner DP. Review of Critical Illness Myopathy and Neuropathy. Neurohospitalist. 2017;7(1):41-8. Disponible en: https://doi.org/10.1177/1941874416663279.
Zink W, Kollmar R, Schwab S. Critical illness polyneuropathy and myopathy in the intensive care unit. Nat Rev Neurol. 2009;5(7):372-9. Disponible en: https://doi.org/10.1038/nrneurol.2009.75.
Ibarra-Estrada MA, Briseño-Ramírez J, Chiquete E, Ruiz-Sandoval JL. Debilidad adquirida en la Unidad de Cuidados Intensivos: Polineuropatía y miopatía del paciente en estado crítico. Rev Mex Neurocienc. 2010;11(4):289-95.
Latronico N, Bertolini G, Guarneri B, Botteri M, Peli E, Andreoletti S, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients : the Italian multi-centre CRIMYNE study. Crit Care. 2007;11(1):R11. Disponible en: https://doi.org/10.1186/cc5671.
Ahlbeck K, Fredriksson K, Rooyackers O, Måbäck G, Remahl S, Ansved T, et al. Signs of critical illness polyneuropathy and myopathy can be seen early in the ICU course. Acta Anaesthesiol Scand. 2009;53(6):717-23. Disponible en: https://doi.org/10.1111/j.1399-6576.2009.01952.x.
Rocheteau P, Chatre L, Briand D, Mebarki M, Jouvion G, Bardon J, et al. Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy. Nat Commun. 2015;6(5):10145. Disponible en: https://doi.org/10.1038/ncomms10145.
Zochodne DW, Bolton CF, Wells GA, Gilbert JJ, Hahn AF, Brown JD, et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain. 1987;110 (Pt 4):819-41. Disponible en: https://doi.org/10.1093/brain/110.4.819.
Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, et al. The sick and the weak: Neuropathies/myopathies in the critically ill. Physiol Rev. 2021;95(3):1025-109. Disponible en: https://doi.org/10.1152/physrev.00028.2014.
Gugala Z, Cacciani N, Klein GL, Larsson L. Acute and severe trabecular bone loss in a rat model of critical illness myopathy. J Orthop Res. 2022;40(6):1293-300. Disponible en: https://doi.org/10.1002/jor.25161.
Ruiz-Santana S, Arboleda-Sánchez JA, Abilés J. Guidelines for specialized nutritional and metabolic support in the critically-ill patient. Update. Consensus SEMICYUC-SENPE: Nutritional assessment. Nutr Hosp. 2011;26(Suppl 2):12-5.
Schulman RC, Mechanick JI. Metabolic and Nutrition Support in the Chronic Critical Illness Syndrome. Respir Care. 2012;57(6):958-77. Disponible en: https://doi.org/10.4187/respcare.01620.
Ogilvie H, Larsson L. The Effect of Nutritional Status in the Pathogenesis of Critical Illness Myopathy (CIM). Biology (Basel). 2014:3(2):368-82. Disponible en: https://doi.org/10.3390/biology3020368.
Kizilarslanoglu MC, Kuyumcu ME, Yesil Y, Halil M. Sarcopenia in critically ill patients. J Anesth. 2016;30(5):884-90. Disponible en: https://doi.org/10.1007/s00540-016-2211-4.
Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care. 2004;7(4):405-10. Disponible en: https://doi.org/10.1097/01.mco.0000134362.76653.b2.
Tabarki B, Coffinières A, Van den Bergh P, Huault G, Landrieu P, Sébire G. Critical illness neuromuscular disease: clinical, electrophysiological, and prognostic aspects. Arch Dis Child. 2002;86(2):103-7. Disponible en: https://doi.org/10.1136/adc.86.2.103.
Behbehani NA, Al-Mane F, D’yachkova Y, Paré P, FitzGerald JM. Myopathy Following Mechanical Ventilation for Acute Severe Asthma: the role of muscle relaxants and corticosteroids. Chest. 1999;115(6):1627-31. Disponible en: https://doi.org/10.1378/chest.115.6.1627.
Wang W, Xu C, Ma X, Zhang X, Xie P. Intensive Care Unit-Acquired Weakness : A Review of Recent Progress With a Look Toward the Future. Front Med (Lausanne). 2020;7:559789. Disponible en: https://doi.org/10.3389/fmed.2020.559789.
Thille AW, Boissier F, Muller M, Levrat A, Bourdin G, Rosselli S, et al. Role of ICU-acquired weakness on extubation outcome among patients at high risk of reintubation. Crit Care. 2020:24(1):86. Disponible en: https://doi.org/10.1186/s13054-020-2807-9.
Colombia. Ministerio de Salud. Resolución 8430 de 1993 (octubre 4): Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá D.C.; octubre 4 de 1993.
Colombia. Ministerio de la Protección Social. Resolución 2378 de 2008 (junio 25): Por la cual se adoptan las Buenas Prácticas Clínicas para las instituciones que conducen investigación con medicamentos en seres humanos. Bogotá D.C.: Diario Oficial 47033; junio 27 de 2008.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: Guideline for good clinical practice. 1996.
World Medical Association (WMA). WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. Fortaleza: 64th WMA General Assembly; 2013.
Organización Panamericana de la Salud (OPS) y Consejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS). Pautas éticas internacionales para la investigación relacionada con la salud con seres humanos, Cuarta Edición. Ginebra: CIOMS; 2016.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Revista Colombiana de Medicina Física y Rehabilitación
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
